Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + hydrocortisone
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intrathecal
01
Overview
A combination therapy consisting of methotrexate and hydrocortisone, primarily administered intrathecally (directly into the cerebrospinal fluid). This combination is used to treat or prevent central nervous system involvement in various conditions, particularly in aggressive non-Hodgkin lymphoma and leukemia. Studies have shown that prophylactic intrathecal methotrexate and hydrocortisone can reduce CNS recurrence and improve survival rates in patients with aggressive non-Hodgkin lymphoma.
- Other names
- intrathecal methotrexate and hydrocortisone
02
Targets
GR (Glucocorticoid receptor)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on methotrexate + hydrocortisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + hydrocortisone.